Disease/Infection News

RSS

Suneva Medical publishes Artefill data for treatment of atrophic acne scars

Suneva Medical, a privately-held aesthetic medical device company, today announced the publication of an open-label, single center, pilot study on Artefill for the treatment of atrophic acne scars conducted by James M. Spencer, M.D. M.S. and sponsored by Suneva Medical.

8 Oct 2010

Phase I study of Shigella dysenteriae bioconjugate vaccine meets primary, secondary endpoints

GlycoVaxyn AG, a leader in the development of innovative vaccines, announced today that the Phase I study of its Shigella dysenteriae bioconjugate vaccine has been completed and met the primary and secondary endpoints: demonstration of safety and immunogenicity.

8 Oct 2010

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed U.S. physicians with regard to their treatment of skin and skin structure infections.

8 Oct 2010

Spanish mothers more concerned about the safety of childhood vaccines

Researchers from the University of Alicante (UA) taking part in the European VACSATC project have studied mothers' and fathers' opinions on vaccinating their children in five countries. The results of the survey show that Spanish mothers are more resistant than those in other countries to the idea of paying for vaccines, while 20.9% expressed some concern about the safety of vaccines.

8 Oct 2010

CDC issues new universal influenza vaccination recommendation for all Americans

With the influenza vaccine already available and more supply anticipated than ever before, the National Foundation for Infectious Diseases convened ten of the country's leading medical and public health groups to call on all Americans to get vaccinated this season.

8 Oct 2010

IV ibuprofen effective in reducing fever in hospitalized patients

Cumberland Pharmaceuticals Inc. today announced the publication of data affirming the safety and efficacy of Caldolor (ibuprofen) Injection in treating fever in critically ill and non-critically ill adults. Published in the peer-reviewed journal Critical Care, the study showed that IV ibuprofen was significantly more effective at reducing fever in hospitalized patients than placebo.

8 Oct 2010

Dengue fever spreads in Asia, WHO warns 2.5B people at risk

The WHO "has warned that 2.5 billion people are at risk" of dengue fever, "which has 'grown dramatically in recent decades,'" Agence France-Presse reports. WHO officials cite higher temperatures, growing populations and international travel for the "rapid rise in urban mosquito populations" and in dengue. Seventy percent of the at-risk population is in Asia, the WHO said.

8 Oct 2010

Scientists engineer bacterial cell wall with small molecules to combat diseases

A team of Yale University scientists has engineered the cell wall of the Staphylococcus aureus bacteria, tricking it into incorporating foreign small molecules and embedding them within the cell wall.

8 Oct 2010

Tight finances creates competition among AIDS researchers

As the economic downturn depresses global investment in AIDS prevention, scientists and those who fund them are struggling to set priorities among several competing research methods that could slow the spread of the disease, which causes about 2.7 million new infections worldwide a year, CQ HealthBeat reports.

8 Oct 2010

VentiRx announces VTX-1463 trial results for allergic rhinitis treatment

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today results from its randomized, placebo controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.

8 Oct 2010

NIAID announces three new contracts to fund research on dengue, anthrax vaccines

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today announced three new contracts to fund research on vaccines to protect against emerging infectious diseases and biological threats that could be used in a terror attack. Each project focuses on simple and efficient vaccine delivery approaches that could be deployed quickly. The total funding for the three contracts could reach $68 million, depending on the successful completion of defined project milestones.

8 Oct 2010

International scientific conference explores new approaches to prevent infectious diseases

Swine flu, cancer, bioterrorism and the latest trends in countermeasures to combat these life-threatening diseases and infections are among the topics to be discussed at the upcoming New Cells for New Vaccines V: Global Perspectives international scientific conference, on October 11-13 in Wilmington, Delaware, at the Hotel du Pont.

8 Oct 2010

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen's tetravalent dengue vaccine, DENVax delivered with PharmaJet's convenient needle-free injection device.

8 Oct 2010

Increased global attention, research needs to be given to stroke prevention: UEA

Increased global attention and research needs to be given to stroke prevention and the social and economic effects of the condition in developing countries, according to an academic at the University of East Anglia.

8 Oct 2010

NIAID awards $6.25M to Profectus to optimize portfolio of genetic adjuvants

Profectus BioSciences, Inc., a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases, today announced that it has received $6.25M in National Institute of Allergy and Infectious Disease (NIAID) grants and contracts.

8 Oct 2010

FDA files complaint for permanent injunction against Brooklyn Juice Company

At the request of the U.S. Food and Drug Administration, the U.S. Department of Justice today filed a complaint for permanent injunction against a Brooklyn juice company to prevent it from processing and distributing juice products.

8 Oct 2010

CQ Healthbeat examines HIV prevention research funding

The global economy has affected HIV/AIDS prevention research, so "scientists and those who fund them are struggling to set priorities among several competing research methods that could slow the spread of the disease, which causes about 2.7 million new infections worldwide a year," CQ HealthBeat reports.

8 Oct 2010

HIV/AIDS needs more funding: Report

Experts have said that just controlling HIV and AIDS would require finances to the tune of $397bn and $733bn over the next 20 years and unless more money is spent the pandemic will continue to spread. They said that funds need to increase from 2009 otherwise the infections could rise from 2.3 million a year to 3.2 million by 2031. This appeared in a report by the aids2031 financing group, headed by the Results for Development Institute in Washington DC.

8 Oct 2010

Mass. attorney general recommends approval of Caritas sale; Calif. will require students to get whooping cough vaccine

Attorney General Martha Coakley yesterday recommended approval of the proposed sale of Caritas Christi Health Care to a New York private equity firm, a deal that would bring for-profit health care on a large scale to a state long dominated by nonprofit hospitals.

8 Oct 2010

Researchers develop algorithm to integrate genomic and metabolic data

Researchers at the Institute for Genomic Biology at the University of Illinois have developed a way to harness the prodigious quantities of both genomic and metabolic data being generated with high-throughput genomics and other techniques. They have developed an algorithm that automatically integrates both data sets. The model, called probabilistic regulation of metabolism (PROM), enables researchers to perturb a given regulatory gene or metabolic process and see how that affects the entire network.

7 Oct 2010